KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Market Cap	89.04B +13.5%
Revenue (ttm)	133.26B +9.6%
Net Income	10.77B +179.9%
EPS	187.40 +179.9%
Shares Out	57.45M
PE Ratio	8.27
Forward PE	19.56
Dividend	52.00 (3.35%)
Ex-Dividend Date	Mar 30, 2026

Volume	207,500
Average Volume	103,925
Open	1,545.00
Previous Close	1,543.00
Day's Range	1,521.00 - 1,554.00
52-Week Range	1,359.00 - 1,725.00
Beta	-0.04
RSI	33.82
Earnings Date	May 12, 2026

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1923
• Employees: 1,998
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4569

Financial Performance

In fiscal year 2025, KYORIN Pharmaceutical's revenue was 130.09 billion, an increase of 8.83% compared to the previous year's 119.53 billion. Earnings were 9.09 billion, an increase of 70.73%.